Nivolumab,Ipilimumab
bms
['cross tumor']
 in an era of #precisionmedicine &amp; provocative data for msi-high across tumor types, it ll be challenging to do randomized trials. remember the agnostic approvals of #immunotherapy &amp; #ntrk were single-arm studies. for #coloncancer has an io arm? #esmo22
Oncologist | Researcher | ColorectalCancer #CRCSM???????@MayoClinic @PittTweet Alum; ??#ctDNA #LiquidBiopsies??#PrecisionOncology ViewsMy Own. COI @ASCO #ASCO22